SAINT LAURENT, QUEBEC and GREAT FALLS, VIRGINIA--(Marketwire - October 09, 2008) - IntelGenx Corp. (TSX: IGX)(OTCBB: IGXT) ("IntelGenx") and Cary Pharmaceuticals Inc. ("Cary Pharma") today announced positive results from a clinical trial on its antidepressant CPI 300. The results from the bioequivalence study undertaken in September 2008 confirm that CPI 300 is bioequivalent to the reference product. IntelGenx and Cary Pharma will be filing a New Drug Application ("NDA") (505(b)(2) based on the successful results of this study. Approval of the product is expected during the second half of 2009.
